Drug Details

General Information of the Drug (ID: DR9868)
Name
HA14-1
Synonyms
Ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate; HA 14-1; Ethyl [2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)]-4H-chromene-3-carboxylate; MFCD00218213; HA-14-1; Ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-1-benzopyran-3-carboxylate; 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-1-benzopyran-3-carboxylic acid ethyl ester; 927635-64-1; SR-01000511000; C17H17BrN2O5; Maybridge1_000786; 2-oxo-2-(2-(tritylamino)thiazol-5-yl)acetic acid; BSPBio_001583; KBioGR_000303; KBioSS_000303; cc-453; SCHEMBL1427458; CHEBI:94328; HMS543L16; KBio2_000303; KBio2_002871; KBio2_005439; KBio3_000605; KBio3_000606; AOB6777; DTXSID20274403; EX-A148; Bio2_000303; Bio2_000783; HMS1361P05; HMS1791P05; HMS1989P05; HMS3268C09; HMS3414M05; HMS3678M05; BCP01804; ABP000246; BTB 02933; HA 141; HA14-1/HA141; HSCI1_000186; NSC720569; AKOS007930839; BCP9000758; CCG-233971; NSC-720569; QC-8196; 2-Amino-6-bromo-alpha-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic acid ethyl ester; IDI1_034053; SMP2_000039; NCGC00025207-02; NCGC00025207-03; NCGC00025207-04; NCGC00025207-05; NCGC00025207-06; NCGC00025207-12; NCGC00025207-15; NCGC00025207-16; AC-32822; AK687960; NCI60_041312; PS-10256; AB0008001; DB-011974; FT-0761318; Y9750; HA 14-1, >=95% (CHN/NMR), powder; S-7766; J-520710; SR-01000511000-1; SR-01000511000-2; BRD-A13807286-001-03-9; Q27166151; 2-Amino-6-bromo-?-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic acid ethyl ester; (; inverted exclamation markR,4R)-rel-2-amino-6-bromo-; A-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic acid, ethyl ester; (alphaR,4R)-rel-2-amino-6-bromo-alpha-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-aceticacid,ethylester
    Click to Show/Hide
Molecular Type
Small molecule
Disease Colon cancer [ICD-11: 2B90] Investigative [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C17H17BrN2O5
PubChem CID
3549
Canonical SMILES
CCOC(=O)C1=C(OC2=C(C1C(C#N)C(=O)OCC)C=C(C=C2)Br)N
InChI
1S/C17H17BrN2O5/c1-3-23-16(21)11(8-19)13-10-7-9(18)5-6-12(10)25-15(20)14(13)17(22)24-4-2/h5-7,11,13H,3-4,20H2,1-2H3
InChIKey
SXJDCULZDFWMJC-UHFFFAOYSA-N
CAS Number
CAS 65673-63-4
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Apigenin      Psilotum nudum     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation		 Up-regulation Expression CAPN1  Molecule Info 
Pathway MAP
Up-regulation Cleavage CASP3  Molecule Info 
Pathway MAP
Up-regulation Cleavage CASP8  Molecule Info 
Pathway MAP
Down-regulation Expression EGFR  Molecule Info 
Pathway MAP
Down-regulation Expression VEGFA  Molecule Info 
Pathway MAP
                    Biological
                    Regulation		 Up-regulation Ratio of Bax to Bcl-2
Up-regulation Cytochrome c release
                    In-vitro Model SK-N-DZ CVCL_1701 Neuroblastoma Homo sapiens
SH-SY5Y CVCL_0019 Neuroblastoma Homo sapiens
IMR-32 CVCL_0346 Neuroblastoma Homo sapiens
                    Experimental
                    Result(s)		 Bcl-2 inhibitor and apigenin worked synergistically in human malignant neuroblastoma cell lines and increased apoptosis with activation of extrinsic and intrinsic pathways.
          Genistein      Glycine max     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [3]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation		 Up-regulation Expression AIFM1  Molecule Info 
Pathway MAP
Up-regulation Expression BAX  Molecule Info 
Pathway MAP
Down-regulation Expression BCL-2  Molecule Info 
Pathway MAP
Up-regulation Expression BID  Molecule Info 
Pathway MAP
Down-regulation Expression BIRC5  Molecule Info 
Pathway MAP
Up-regulation Expression CAPN1  Molecule Info 
Pathway MAP
Up-regulation Cleavage CASP3  Molecule Info 
Pathway MAP
Up-regulation Cleavage CASP8  Molecule Info 
Pathway MAP
Up-regulation Expression DIABLO  Molecule Info 
Pathway MAP
Down-regulation Expression NMI  Molecule Info 
Pathway MAP
Down-regulation Expression p105  Molecule Info 
Pathway MAP
                    Biological
                    Regulation		 Up-regulation Cytochrome c release
                    In-vitro Model SK-N-BE(2) CVCL_0528 Neuroblastoma Homo sapiens
SH-SY5Y CVCL_0019 Neuroblastoma Homo sapiens
                    Experimental
                    Result(s)		 Combination of HA and GST was more effective in inducing apoptosis in both cell lines than either HA or GST alone by down-regulating survival factors and activating cysteine proteases for apoptosis.
Target and Pathway
Target(s) Telomerase protein component 1 (TEP1)  Molecule Info  [4]
References
Reference 1 Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis is inhibited by Bcl-2 but restored by the small molecule Bcl-2 inhibitor, HA 14-1, in human colon cancer cells. Clin Cancer Res. 2004 Dec 15;10(24):8284-92.
Reference 2 Bcl-2 inhibitor and apigenin worked synergistically in human malignant neuroblastoma cell lines and increased apoptosis with activation of extrinsic and intrinsic pathways. Biochem Biophys Res Commun. 2009 Oct 30;388(4):705-10.
Reference 3 Bcl-2 inhibitor HA14-1 and genistein together adeptly down regulated survival factors and activated cysteine proteases for apoptosis in human malignant neuroblastoma SK-N-BE2 and SH-SY5Y cells. Brain Res. 2009 Aug 4;1283:155-66.
Reference 4 Long-term in vitro treatment with telomerase inhibitor MST-312 induces resistance by selecting long telomeres cells. Cell Biochem Funct. 2019 Jun;37(4):273-280.
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link